Introduction {#S0001}
============

*Helicobacter pylori* (*H. pylori*) are curved, gram-negative, microaerophilic bacteria[@CIT0001] found in the gastric mucous layer or adherent to the epithelial lining of the stomach.[@CIT0002] It has been a public health significance bacteria since 1983 as it infects the duodenum where hydrochloric acid and pepsin play a role in the digestion of food, which facilitates damage of the lining by gastric acid.[@CIT0003] *H. pylori* can elevate acid secretion in people who develop duodenal ulcers[@CIT0004] or hypersecretion of gastric acid can by itself evoke duodenal ulcers.[@CIT0005]

The prevalence and the severity of the infection vary considerably among populations[@CIT0006] due to geographical differences and ways of leading life.[@CIT0004] In the US, 30--40% of people are infected with *H. pylori*[@CIT0007] and the prevalence is still high in Eastern Mediterranean countries of the healthy asymptomatic population.[@CIT0008] Most of the infection occurred during childhood with no difference in gender.[@CIT0009]

Before the discovery of *H. pylori*, spicy food, acid, stress, and lifestyle were considered to be the causes of ulcers.[@CIT0002] Age, religion, and water sources are risk factors for *H. pylori* infection in Indonesia.[@CIT0010] Poor socio-economic status, genetic predisposition, and being resident in a developing country are among known risk factors for *H. pylori* infection.[@CIT0011] Sharing food or eating utensils, contact with contaminated water and with the stool, saliva, or vomit of an infected person are also potential risk factors.[@CIT0003],[@CIT0011]

Dye endoscopy, forceps biopsies for culture, histology, and rapid urease test are used for diagnosis of *H. pylori* infection, and a patient is considered negative when the serum anti-*H*. *pylori* IgG and the three tests on biopsied specimens are all negative.[@CIT0012] *H. pylori* are associated with an increased risk for the development of duodenal and gastric ulcers, gastric adenocarcinoma, and gastric B-cell lymphoma.[@CIT0006],[@CIT0009] The bacterium attaches to epithelial cells of the stomach and duodenum, then it causes damage to the cells by secreting degradative enzymes (urease, lipases, and proteases) and bacterial virulence factors (cytotoxin-associated gene protein (CagA) and vacuolating cytotoxin (VacA)), and initiating a self-destructive immune response.[@CIT0013] Eradication of infection reduces the risk of duodenal ulcer,[@CIT0014] but the outcome depends on the extent of host response to the infection like gastric inflammation and the amount of acid secretion by parietal cells.[@CIT0004] This review article aims to explore the controversies on the causal role of *H pylori* in duodenal ulcers.

Methods {#S0002}
=======

Studies were obtained from electronic databases, including Google Scholar, PubMed, Hinari, Web of Science, Scopus, and Science Direct, with hand searches and iterative reviews of reference lists of papers using the keywords "*H. Pylori"*, "duodenal ulcer", "causation" and in combination from February 7--13, 2019. A total of 107 papers were obtained from all sources. After the exclusion of redundant and irrelevant literature, a total of 26 separate published empirical articles ([Table 1](#T0001){ref-type="table"}) in peer-reviewed journals were reviewed. The searching process is displayed in [Figure 1](#F0001){ref-type="fig"}.Table 1Study Characteristics Of Reviewed ArticlesNoAuthorStudy DesignSample SizeYearCountryMethodResult1Carrick J, Lee A, Hazell S, Ralston M, Daskalopoulos GCohort1371989AustraliaCongo Red stainingStrong risk factor (RR=51)[@CIT0021]2Moss SF, Calam JRandomized clinical trial91993EnglandEndoscopy and biopsiesEradication reduce basal plasma gastrin concentration (*P*\<0.05), and basal acid secretion (*P*\<0.01)[@CIT0039]3Reinbach DH, Cruickshank G, McColl KEMatched hospital case control801993United KingdomSerum anti-H pylon IgG and '4C-urea breath testsPrevalence 47%[@CIT0032]4Batista SA, et alExperimental1122011BrazilEndoscopyNumber of EPIYA C segments did not associate with duodenal ulcer[@CIT0041]5Cekin AH, et alMatched case control2222012TurkeyEsophago-gastroduodenoscopy*H. pylori* located in the corpus \[OR\]=3.00; incisura OR=2.07; and antrum \[OR\]=2.71. *Hp* positivity was 84.9%[@CIT0027]6Gisbert JP, et alCross-sectional7741999SpainEndoscopyPrevalence 95.3%[@CIT0034]7Tsuji H, et alCross-sectional1201999JapanEndoscopic, rapid urease test and forceps biopsies1.7% *H. pylori*-negative rates[@CIT0012]8Gdalevich M, et alNested case control292000IsraelELISA IgG-AbOR=3.8[@CIT0031]9Khan MM, Shahzed MN, Jibran M, Rabbani MJCross-sectional1162009PakistanACON®116 patients (92 males and 24 females) have perforated DU and more common in 30--50 age groups[@CIT0048]10Lario S, et alCohort882013SpainMicroarraysHigher levels of IL8 and IL12p40 mRNAs and lower levels of GATA6 and SOCS2 mRNAs[@CIT0049]11Labenz JO, et alCross-sectional161996GermanypH metry, glass electrode, urea breath test, culture, histology, and rapid urease*H. pylori* eradication decrease the pH-increasing effect of omeprazole; *P*\<0.002[@CIT0036]12Olbe L, Hamlet A, Dalenback J, Fandriks LCross-sectional161996SwedenUrea breath test, culture, histology, and rapid ureaseInhibitory mechanism was restituted in 8 of 10 patients within 9 months after eradication of *H. pylori* infection[@CIT0005]13Chu KM, Kwok KF, Law S, Wong KHCross-sectional13432005ChinaEndoscopic, rapid urease test and biopsiesMale preponderance (M:F=2.5:1)[@CIT0013]14Syam AF, et alCross-sectional2672014IndonesiaCulture, histology\
and rapid urease testPrevalence 22.1%[@CIT0010]15Segal ED, Cha J, Lo J, Falkow S, Tompkins LSLaboratory1999USAELISA IgG-Ab145-kDa protein and activation of signal transduction pathways associated with the attachment of *H. pylori[@CIT0019]*16Borody TJ, et alCohort3021991Endoscopic, rapid urease test and biopsies94% were found to have associated *H pylori[@CIT0044]*17Ng EK, et alCohort731996Intra-operative gastroscopy and antral biopsies70% had evidence of *H. pylori[@CIT0033]*18Rauws EA, Tytgat GNRandomized clinical trial501990Eradication achieved 7 of the 45 patients and there was no ulcer relapse during the first 12 months of follow-up[@CIT0038]19Patchett S, Beattie S, Leen E, Keane C, O'Morain CCohort511992Endoscopic, biopsiesRecurrence of *H. pylori* infection occurred in 35.3%[@CIT0029]20Chan FKRandomized clinical trial1001997Hong KongEndoscopyEradication of *H pylori* before NSAID therapy reduces the occurrence[@CIT0016]21Blaser MJ, Chyou PH, Nomura ACase control3131995USA*H. pylori* do not increases risk of developing duodenal ulcer[@CIT0040]22Nomura A, Stemmermann GN, Chyou PH, Perez-Perez GI, Blaser MJNested case control54431994USAELISA IgG-Ab92% patients and 78% of the matched controls had a positive test result, OR=4.0[@CIT0028]23Kim JG, Graham DYCross-sectional1811994ELISA IgG-Ab36% developed a duodenal ulcer[@CIT0045]24Borody TJ, Brandl S, Andrews P, Jankiewicz E, Ostapowicz NCross-sectional1151992AustraliaEndoscopy47 (66%) no detectable causal factors, 21 (30%) regularly taking NSAIDs, and three (4%) had malignant GU[@CIT0017]25Bytzer P, Teglbjærg PS, Group DURandomized clinical trial2762001Culture, immunohistochemistry, and urea breath testEradication therapy over 2 years is significantly poorer in *H. pylori*-negative patients[@CIT0007]26Escobar MA, et alCross-sectional169200412% of patients develop late complications[@CIT0026]

The inclusion criteria were: type of study; randomized clinical trial, case-control, cohort, ecological, and cross-sectional, and systematic review, publication; academic journal (peer-reviewed) and non-reviewed reports, population; Global, time-period: 1989 to present, and language; English. Figure 1Data searching process.

Result And Discussion {#S0003}
=====================

Evidence On Causal Relation Between *H. pylori* Infection And Duodenal Ulcer {#S0003-S2001}
----------------------------------------------------------------------------

*H. pylori* has a role in the etiology of duodenal ulcer.[@CIT0015]^--^[@CIT0017] Once ingested, the attachment of *H. pylori* to epithelial cells of the stomach and duodenum occurs through phosphorylation of a 145 kilo Dalton protein and activation of signal transduction pathways.[@CIT0018],[@CIT0019] *H. pylori* infection blocks normal physiological mechanisms resulting in increased gastrin release and impaired inhibition of gastric acid secretion.[@CIT0018],[@CIT0020] Such endogenous hypersecretion of acid causes gastric metaplasia[@CIT0004] and synergizes ulceration.[@CIT0021] Thus, the prevalence of *H. pylori* infection in duodenal ulcer patients is higher than the normal population,[@CIT0022] as patients are more likely to be infected with virulent strains which later cause duodenal ulceration.[@CIT0023] The disease manifestations start when alteration of epithelial cell growth and enhanced apoptosis occur.[@CIT0024] *H. pylori* containing functional Cag pathogenicity island produce a vigorous inflammatory response,[@CIT0025] and 12% of patients develop late complications with a further 6% mortality rate.[@CIT0026]

*H. pylori* plays a role in the pathogenesis of duodenal ulcer disease in 84.9% of subjects and the single causative factor in 44.1% of patients.[@CIT0027] Duodenal infection with *H. pylori* is a strong risk factor (RR=51),[@CIT0021] (OR=4)[@CIT0028] for the development of duodenal ulceration. Antral reinfection with *H. pylori* is also associated with relapse[@CIT0029] (RR=7.6).[@CIT0021] This evidence supports a strong causal relation between *H. pylori* infection and duodenal ulceration.[@CIT0030]

Preexisting history of *H. pylori* is a risk for the development of duodenal ulcer,[@CIT0028] and it is observed that in young Israelis with an odds ratio of 3.8, the association increased as diagnosis time exceeded 2 years with 56.6% attributable risk.[@CIT0031]

Although cigarette smoking, age, sex, and ingestion of non-steroidal anti-inflammatory drugs (NSAID) were not found to be significant risk factors for duodenal ulceration,[@CIT0021],[@CIT0032] *H. pylori* infection plays a role in the causation of non-NSAID-induced duodenal ulcer perforation.[@CIT0033] Excluding patients taking NSAIDs and/or antibiotics, *H. pylori* prevalence increased up to 99.1% (98.1±99.6%) among duodenal ulcer patients.[@CIT0034]

The current therapy for *H. pylori* induced ulcer (a proton pump inhibitor and at least two antimicrobials with or without bismuth) is highly effective in eradicating the infection.[@CIT0009] Eradication of *H. pylori* infection decreases the incidence of duodenal ulcer and prevents its recurrence,[@CIT0022],[@CIT0035]^--^[@CIT0037] and the occurrence of NSAID induced peptic ulcers[@CIT0016] without altering acid output.[@CIT0038] As a result, eradication resulted in falls in both basal gastrin release and acid secretion without affecting parietal cell sensitivity.[@CIT0039] On the other hand, the clinical outcome of eradication therapy over 2 years is significantly poorer in *H. pylori*-negative patients.[@CIT0007]

Evidence Against Causal Relation Between *H. pylori* Infection And Duodenal Ulcer {#S0003-S2002}
---------------------------------------------------------------------------------

A cohort study of 73 participants revealed that prior life acquisition of *H. pylori* was not associated with duodenal ulcer[@CIT0040] and only a minority of infected persons develop duodenal ulceration.[@CIT0022] This indicates that different pathogenesis had existed for duodenal ulceration.[@CIT0032] Moreover, *H. pylori* strain with high number of CagA EPIYA-C segments was not associated with duodenal ulcer.[@CIT0041]

Duodenal ulcer can relapse after eradication of *H. pylori* infection, and the ulcer may remain healed after reduction of acid secretion in the presence of infection. Additionally, hypersecretion of gastric acid is strongly associated with the development of duodenal ulcers while it may result in a spontaneous eradication of *H. pylori* infection.[@CIT0023] The virulent strains cause delayed healing of an ulcer produced by acid hypersecretion[@CIT0042] by interfering with neoangiogenesis of wounded duodenal epithelial cells[@CIT0023] indicating the bacteria delay the healing of ulcer rather than causing it.

The annual proportion of patients with *H. pylori*-negative duodenal ulcers increased as the ulcers are more likely to occur in individuals with old age, pre-existing malignancy, recent surgery, underlying sepsis,[@CIT0043] NSAID use,[@CIT0043]^--^[@CIT0045] a concomitant medical problem like Crohn's disease and hypergastrinaemia,[@CIT0046] specific geographical distribution,[@CIT0047] and recent intake of antibiotics.[@CIT0044] Smoking and the presence of dietary lipids are also risk factors.[@CIT0004],[@CIT0023] Among 71 *H. pylori-*positive duodenal ulcer patients, 66% had no other detectable causal factors, 30% were regularly taking NSAIDs, and 4% had malignancy.[@CIT0017] Thus, *H. pylori* is not the primary cause of duodenal ulcer.[@CIT0047]

Evaluation Of Causal Relation Between *H. pylori* Infection And Duodenal Ulcer Through Hill's Criteria {#S0003-S2003}
------------------------------------------------------------------------------------------------------

The review assessed the causal relation between *H. pylori* infection and duodenal ulcer by using criteria for assessing causation proposed in 1965 by Sir Austin Bradford Hill. Despite controversies observed on the causal role of *H. pylori* to duodenal ulceration in various literature, Hill criteria of causation proved a causal relation between *H. pylori* infection and duodenal ulcer ([Table 2](#T0002){ref-type="table"}). Table 2Hill Criteria For Assessing The Causal Role Of *H. Pylori* On Duodenal UlcerSr. NoHill Criteria'sDescription1Biological plausibilityBiologically plausible explanations for causation exist.[@CIT0018]^--^[@CIT0020]2Dose response relationshipEradication of *H. pylori* infection decreases the incidence of duodenal ulcer and prevents its recurrence.[@CIT0022],[@CIT0035]^--^[@CIT0037],[@CIT0039]3Strength of associationStrong association.[@CIT0021],[@CIT0028],[@CIT0029]4ConsistencyThe association between *H. pylori* and duodenal ulcer has been consistently demonstrated in a number of different types of epidemiological studies (ecological, case-control, cohort, randomized clinical trial and cross-sectional).5TemporalityProved in epidemiological studies (case-control, cohort, randomized clinical trial)6Study designAll types of epidemiological study designs (ecological, case-control, cohort, randomized clinical trial, and cross-sectional).7ReversibilityThe removal of a possible cause (*H. pylori*) led to reduction of disease risk.[@CIT0022],[@CIT0035]^--^[@CIT0037],[@CIT0039]8Specificity of associationNo, exposure to *H. pylori* is also associated with other diseases like gastric ulcer,[@CIT0031],[@CIT0040] gastric cancer,[@CIT0028],[@CIT0041] gastro esophageal reflex disease.[@CIT0025]

Conclusion {#S0004}
==========

There are controversies among studies on the causal relation between *H. pylori* infection and duodenal ulcer. Several studies reported *H. pylori* is a strong risk factor for the development of duodenal ulcers, whereas other studies showed duodenal ulcers can recur after eradication of *H. pylori* infection, and the ulcer may remain healed after reduction of acid secretion in the presence of active infection, indicating the absence of a causal relation between *H. pylori* infection and duodenal ulcer. Despite controversies observed in the causal role of *H. pylori* to duodenal ulcer by various studies, critical examination of empirical evidence through Hill criteria of causation proved the presence of a causal relation between *H. pylori* infection and duodenal ulcer.
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